Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
Biomarkers, Tumor
Breast Neoplasms
/ drug therapy
Drug Administration Schedule
Drug Monitoring
Female
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Treatment Outcome
Prolactin receptor
breast cancer
prostate cancer
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
21
07
2020
revised:
27
07
2020
accepted:
28
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
20
9
2020
Statut:
ppublish
Résumé
The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclinical antitumor activity. To determine the maximum tolerated dose or a recommended dose, and to delineate the pharmacokinetic profile of LFA102 in Japanese patients, we conducted a phase I study. LFA102 was intravenously infused every 4 weeks to patients with advanced breast or castration-resistant prostate cancer, and the dose increased from 3 to 40 mg/kg. Fourteen patients were treated, and toxicities were reported in 9 (64%) patients. They were all grade 1 or 2, and the most frequently observed toxicity was nausea (3 patients, 21%). No dose-limiting toxicities were observed. LFA102 did not show antitumor activity as a single agent. Treatment with LFA102 was well tolerated.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The prolactin receptor (PRLR) is implicated in the tumorigenesis of breast and prostate cancers where it drives cell proliferation, survival, and migration. LFA102 is a humanized monoclonal antibody against PRLR with promising preclinical antitumor activity. To determine the maximum tolerated dose or a recommended dose, and to delineate the pharmacokinetic profile of LFA102 in Japanese patients, we conducted a phase I study.
PATIENTS AND METHODS
METHODS
LFA102 was intravenously infused every 4 weeks to patients with advanced breast or castration-resistant prostate cancer, and the dose increased from 3 to 40 mg/kg.
RESULTS
RESULTS
Fourteen patients were treated, and toxicities were reported in 9 (64%) patients. They were all grade 1 or 2, and the most frequently observed toxicity was nausea (3 patients, 21%). No dose-limiting toxicities were observed. LFA102 did not show antitumor activity as a single agent.
CONCLUSION
CONCLUSIONS
Treatment with LFA102 was well tolerated.
Identifiants
pubmed: 32878811
pii: 40/9/5229
doi: 10.21873/anticanres.14526
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
LFA102 monoclonal antibody
0
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5229-5235Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.